News

Introducing Our Most Robust Muscular Dystrophy/Myopathy Panels

Muscular dystrophies and myopathies are complex conditions and we strive to stay at the forefront of genetics to provide you with the best answers possible. The correct genetic diagnosis is vital to the patient meaning pinpointing treatment options and therapies, and opening up the possibility of clinical trial enrollment downstream. MNG Laboratories has made substantial improvements in our ability to search for and identify the known pathogenic variants likely to cause Muscular Dystrophy and Muscular Myopathy. We routinely review over 9,200 disease causing variants in genes associated with conditions that are linked to muscular dystrophy; that’s approximately 145% more than our closest competitor and as much as 11 times that of others. We include mtDNA and Deletion/Duplication analysis to provide you with the most comprehensive testing possible.

Comprehensive Muscular Dystrophy/Myopathy Panel

Understanding that a comprehensive panel may not always be necessary, we also updated 3 of our existing subpanels to cover more genes and ensure greater identification of known pathogenic variants: In addition, we have introduced 4 new subpanels to our muscular dystrophy portfolio: Our robust portfolio allows you the opportunity to choose between a comprehensive phenotype-driven panel or a more targeted syndrome-specific panel. We also include Copy Number Analysis and mtDNA sequencing and deletion/duplication analysis to provide you with the most clinically sensitive testing possible.